SCL Science Signs Technology Transfer Agreement with KAIST

Accelerating the Development of a New Drug Discovery Platform

(From left) Professor Jungkyun Choi of KAIST, Professor Jongeun Park of KAIST, Chairman Kyungryul Lee of SCL Group, and CEO Seyun Baek of SCL Science are taking a commemorative photo after signing the technology transfer agreement.

SCL Science announced on September 9 that it has signed a technology transfer agreement with KAIST for the "Single-Cell Big Data Warehouse" technology.

This technology is a major research achievement of the SCL-KAIST Translational Medicine Research Institute, which was launched in November last year. In collaboration with the research team led by Jeonggyun Choi, a professor at KAIST and an outside director of SCL Science, public single-cell omics data is collected to build a standardized database (DB) that includes information on the status of human organ tissues, cellular composition, and correlations with diseases.

Single-cell omics is an advanced technology that analyzes various biomolecular information at the individual cell level, enabling precise identification of the unique molecular characteristics and heterogeneity of each cell. Through this technology transfer, SCL Science will accelerate the development of an AI-based single-cell analysis platform. The platform will then be utilized across the field of precision medicine, including the discovery of disease diagnostic markers, the development of new drug candidates, and the establishment of patient group classification systems.

Professor Choi stated, "Traditional analyses at the tissue or cell population level have made it difficult to precisely interpret cellular heterogeneity or the tumor microenvironment. The single-cell data warehouse will contribute to the establishment of precision-targeted treatment strategies by reliably collecting and analyzing high-resolution data."

He added, "By integrating SCL Group's real-world testing and screening data, we can build a precision medicine drug development platform that covers everything from new drug candidate discovery to companion diagnostics. This platform can also be applied to precision medicine research related to cancer."

Last year, SCL Science and KAIST established the Translational Medicine Research Institute and signed a memorandum of understanding (MOU) for a medical data bio platform. By combining SCL Group's resources in screening and specimen data with KAIST's data analysis capabilities, they are strengthening their competitiveness in the digital healthcare business.